JP2011507861A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011507861A5 JP2011507861A5 JP2010539518A JP2010539518A JP2011507861A5 JP 2011507861 A5 JP2011507861 A5 JP 2011507861A5 JP 2010539518 A JP2010539518 A JP 2010539518A JP 2010539518 A JP2010539518 A JP 2010539518A JP 2011507861 A5 JP2011507861 A5 JP 2011507861A5
- Authority
- JP
- Japan
- Prior art keywords
- connexin
- composition
- polynucleotide
- medicament
- item
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000000203 mixture Substances 0.000 claims description 79
- 238000000034 method Methods 0.000 claims description 58
- 108091033319 polynucleotide Proteins 0.000 claims description 58
- 239000002157 polynucleotide Substances 0.000 claims description 58
- 102000040430 polynucleotide Human genes 0.000 claims description 58
- 230000000692 anti-sense effect Effects 0.000 claims description 44
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 38
- 239000003795 chemical substances by application Substances 0.000 claims description 37
- 239000008194 pharmaceutical composition Substances 0.000 claims description 37
- 230000003176 fibrotic effect Effects 0.000 claims description 30
- 239000003814 drug Substances 0.000 claims description 29
- 206010016654 Fibrosis Diseases 0.000 claims description 24
- 230000004761 fibrosis Effects 0.000 claims description 24
- 239000000816 peptidomimetic Substances 0.000 claims description 22
- 241000124008 Mammalia Species 0.000 claims description 20
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 20
- 102000001045 Connexin 43 Human genes 0.000 claims description 16
- 108010069241 Connexin 43 Proteins 0.000 claims description 16
- 241001465754 Metazoa Species 0.000 claims description 16
- 102000010970 Connexin Human genes 0.000 claims description 15
- 108050001175 Connexin Proteins 0.000 claims description 15
- 108020004999 messenger RNA Proteins 0.000 claims description 12
- 239000002773 nucleotide Substances 0.000 claims description 12
- 125000003729 nucleotide group Chemical group 0.000 claims description 12
- 201000010099 disease Diseases 0.000 claims description 10
- 208000035475 disorder Diseases 0.000 claims description 10
- 238000011282 treatment Methods 0.000 claims description 8
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 6
- 108091030071 RNAI Proteins 0.000 claims description 6
- 108020004459 Small interfering RNA Proteins 0.000 claims description 6
- 230000000295 complement effect Effects 0.000 claims description 6
- 238000002844 melting Methods 0.000 claims description 6
- 230000008018 melting Effects 0.000 claims description 6
- 230000004962 physiological condition Effects 0.000 claims description 6
- 101800005309 Carboxy-terminal peptide Proteins 0.000 claims description 4
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 4
- 108091034117 Oligonucleotide Proteins 0.000 claims description 4
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 4
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 4
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims description 4
- 150000001875 compounds Chemical class 0.000 claims description 4
- 210000003976 gap junction Anatomy 0.000 claims description 4
- 244000144972 livestock Species 0.000 claims description 4
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 claims description 4
- 230000002265 prevention Effects 0.000 claims description 4
- 230000006916 protein interaction Effects 0.000 claims description 4
- 238000011200 topical administration Methods 0.000 claims description 4
- 230000003510 anti-fibrotic effect Effects 0.000 claims description 2
- 239000005022 packaging material Substances 0.000 claims description 2
- 229920001983 poloxamer Polymers 0.000 claims description 2
- 238000011321 prophylaxis Methods 0.000 claims description 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims 3
- 230000026731 phosphorylation Effects 0.000 claims 2
- 238000006366 phosphorylation reaction Methods 0.000 claims 2
- 238000002560 therapeutic procedure Methods 0.000 claims 2
- 102100033299 Glia-derived nexin Human genes 0.000 claims 1
- 101000997803 Homo sapiens Glia-derived nexin Proteins 0.000 claims 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims 1
- 238000011257 definitive treatment Methods 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 230000002222 downregulating effect Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US888607P | 2007-12-21 | 2007-12-21 | |
| PCT/US2008/014026 WO2009085275A2 (en) | 2007-12-21 | 2008-12-22 | Use of anti-connexin polypeptide agent in combination with anti-connexin polynucleotide agent for the treatment of fibrotic conditions |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015010581A Division JP2015083606A (ja) | 2007-12-21 | 2015-01-22 | 線維症性の状態の治療のための抗コネキシンポリヌクレオチド剤と組み合わせた抗コネキシンポリペプチド剤の使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011507861A JP2011507861A (ja) | 2011-03-10 |
| JP2011507861A5 true JP2011507861A5 (https=) | 2013-04-25 |
Family
ID=40824959
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010539518A Withdrawn JP2011507861A (ja) | 2007-12-21 | 2008-12-22 | 線維症性の状態の治療のための抗コネキシンポリヌクレオチド剤と組み合わせた抗コネキシンポリペプチド剤の使用 |
| JP2015010581A Pending JP2015083606A (ja) | 2007-12-21 | 2015-01-22 | 線維症性の状態の治療のための抗コネキシンポリヌクレオチド剤と組み合わせた抗コネキシンポリペプチド剤の使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015010581A Pending JP2015083606A (ja) | 2007-12-21 | 2015-01-22 | 線維症性の状態の治療のための抗コネキシンポリヌクレオチド剤と組み合わせた抗コネキシンポリペプチド剤の使用 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20110092449A1 (https=) |
| EP (1) | EP2237795A2 (https=) |
| JP (2) | JP2011507861A (https=) |
| AU (1) | AU2008343756A1 (https=) |
| CA (1) | CA2710387A1 (https=) |
| WO (1) | WO2009085275A2 (https=) |
| ZA (1) | ZA201005222B (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102073629B1 (ko) | 2005-02-03 | 2020-02-05 | 코다 테라퓨틱스 (엔지) 리미티드 | 항-코넥신 화합물 및 그의 용도 |
| UA96457C2 (ru) | 2006-08-03 | 2011-11-10 | Нитек Фарма Аг | Лечение ревматоидного артрита глюкокортикоидами с отсроченным высвобождением |
| EP2245158A2 (en) * | 2007-12-11 | 2010-11-03 | Coda Therapeutics, Inc. | Impaired wound healing compositions and treatments |
| US8975237B2 (en) | 2007-12-21 | 2015-03-10 | Coda Therapeutics, Inc. | Treatment of fibrotic conditions |
| JP5881698B2 (ja) * | 2010-07-19 | 2016-03-09 | ブラセルズ ベンチャーズ コーポレーションＢｒｕｓｅｌｌｓ Ｖｅｎｔｕｒｅｓ Ｃｏｒｐ． | エーテルヒドロキシエチルセルロースを含む抗微生物医療用ジェル |
| DK2819682T3 (en) | 2012-03-01 | 2017-08-21 | Firststring Res Inc | TOPICAL GELLS CONTAINING ALPHA-CONNEXIN C-TERMINAL (ACT) PEPTIDES |
| CN107109410B (zh) | 2014-08-22 | 2021-11-02 | 奥克兰联合服务有限公司 | 通道调节剂 |
| CN109219442A (zh) | 2016-04-04 | 2019-01-15 | Omeza有限公司 | 鱼油局部组合物 |
| CA3022763A1 (en) * | 2016-05-03 | 2017-11-09 | University Of Auckland | Novel peptides and peptidomimetics |
| CA3061738A1 (en) | 2017-04-28 | 2018-11-01 | Auckland Uniservices Limited | Methods of treatment and novel constructs |
| IL297091A (en) * | 2020-04-07 | 2022-12-01 | Firststring Res Inc | Preparations and methods for treating complications from viral infections and other respiratory disorders |
| MX2023004631A (es) | 2020-10-22 | 2023-07-20 | Xequel Bio Inc | Formulaciones peptidicas y usos oftalmicos de las mismas. |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3687808A (en) * | 1969-08-14 | 1972-08-29 | Univ Leland Stanford Junior | Synthetic polynucleotides |
| US5034506A (en) * | 1985-03-15 | 1991-07-23 | Anti-Gene Development Group | Uncharged morpholino-based polymers having achiral intersubunit linkages |
| CA1322714C (en) * | 1986-11-14 | 1993-10-05 | Harry N. Antoniades | Wound healing and bone regeneration |
| JPH0539594Y2 (https=) * | 1988-08-05 | 1993-10-07 | ||
| US5166195A (en) * | 1990-05-11 | 1992-11-24 | Isis Pharmaceuticals, Inc. | Antisense inhibitors of the human immunodeficiency virus phosphorothioate oligonucleotides |
| US20030148968A1 (en) * | 1995-02-28 | 2003-08-07 | Hammond H. Kirk | Techniques and compositions for treating cardiovascular disease by in vivo gene delivery |
| US6752987B1 (en) * | 1995-02-28 | 2004-06-22 | The Regents Of The University Of California | Adenovirus encoding human adenylylcyclase (AC) VI |
| AU9016898A (en) * | 1997-08-07 | 1999-03-01 | United States Of America, Represented By The Secretary, Department Of Health And Human Services, The | Methods and compositions for treatment of restenosis |
| WO1999029858A1 (en) * | 1997-12-09 | 1999-06-17 | Children's Medical Center Corporation | Soluble inhibitors of vascular endothelial growth factor and use thereof |
| US6506559B1 (en) * | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
| EP2314321B1 (en) * | 1999-01-27 | 2014-06-04 | Coda Therapeutics, Inc. | Formulations comprising antisense nucleotides to connexins |
| US5998148A (en) * | 1999-04-08 | 1999-12-07 | Isis Pharmaceuticals Inc. | Antisense modulation of microtubule-associated protein 4 expression |
| US20050119211A1 (en) * | 2001-05-18 | 2005-06-02 | Sirna Therapeutics, Inc. | RNA mediated inhibition connexin gene expression using short interfering nucleic acid (siNA) |
| JP2005509621A (ja) * | 2001-10-17 | 2005-04-14 | ユニバーシティ オブ ウェールズ カレッジ オブ メディスン | ギャップ結合ならびにｅｄｈｆ |
| CN1638790A (zh) * | 2002-01-29 | 2005-07-13 | Wyeth公司 | 用于调节连接蛋白半通道的组合物和方法 |
| WO2003096981A2 (en) * | 2002-05-15 | 2003-11-27 | Seul, Kyung, Hwan | Method of modulating angiogenesis |
| US8809504B2 (en) * | 2002-09-03 | 2014-08-19 | Vit Lauermann | Inhibitor which is deactivatable by a reagent produced by a target cell |
| WO2006006948A2 (en) * | 2002-11-14 | 2006-01-19 | Dharmacon, Inc. | METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY |
| KR101350837B1 (ko) * | 2003-12-03 | 2014-01-14 | 코다 테라퓨틱스, 인크. | 코넥신에 표적화된 안티센스 화합물 및 그의 사용 방법 |
| KR102073629B1 (ko) * | 2005-02-03 | 2020-02-05 | 코다 테라퓨틱스 (엔지) 리미티드 | 항-코넥신 화합물 및 그의 용도 |
| AU2007319811A1 (en) * | 2006-11-15 | 2008-05-22 | Coda Therapeutics, Inc. | Improved methods and compositions for wound healing |
| EP2543377A1 (en) * | 2006-12-11 | 2013-01-09 | Coda Therapeutics, INC. | Anticonnexin polynucleotides as impaired wound healing compositions |
| EP2245158A2 (en) * | 2007-12-11 | 2010-11-03 | Coda Therapeutics, Inc. | Impaired wound healing compositions and treatments |
-
2008
- 2008-12-22 US US12/809,974 patent/US20110092449A1/en not_active Abandoned
- 2008-12-22 AU AU2008343756A patent/AU2008343756A1/en not_active Abandoned
- 2008-12-22 CA CA2710387A patent/CA2710387A1/en not_active Abandoned
- 2008-12-22 JP JP2010539518A patent/JP2011507861A/ja not_active Withdrawn
- 2008-12-22 WO PCT/US2008/014026 patent/WO2009085275A2/en not_active Ceased
- 2008-12-22 EP EP08867884A patent/EP2237795A2/en not_active Withdrawn
-
2010
- 2010-07-21 ZA ZA2010/05222A patent/ZA201005222B/en unknown
-
2015
- 2015-01-22 JP JP2015010581A patent/JP2015083606A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011507861A5 (https=) | ||
| JP2011507860A5 (https=) | ||
| JP2011507855A5 (https=) | ||
| JP2011507858A5 (https=) | ||
| JP2011506447A5 (https=) | ||
| Bartus et al. | Calpain inhibitor AK295 protects neurons from focal brain ischemia. Effects of postocclusion intra-arterial administration. | |
| JP2011508605A5 (https=) | ||
| Wang et al. | Effects of minocycline alone and in combination with mild hypothermia in embolic stroke | |
| JP2019196370A5 (https=) | ||
| US10335455B2 (en) | Method for prevention or treatment of intractable inflammatory bowel disease | |
| JP2013533858A5 (https=) | ||
| CA2730789A1 (en) | Treatment of inflammatory bowel diseases with mammal beta defensins | |
| JP2016516016A5 (https=) | ||
| JP2009544585A5 (https=) | ||
| JP2011528333A5 (https=) | ||
| JPH0245425A (ja) | 脳神経障害治療用薬剤 | |
| JP2021152060A (ja) | アカンプロセートおよびｄ−サイクロセリンを使用する組み合わせ療法 | |
| CN107405315A (zh) | 用于治疗神经肌肉、神经变性、自身免疫、发育和/或代谢疾病的脑源性神经营养因子(bdnf)的诱导表达 | |
| JPWO2019241442A5 (https=) | ||
| JP2016505050A5 (https=) | ||
| Bisht et al. | Effect of fentanyl and nalbuphine for prevention of etomidate-induced myoclonus | |
| US7935718B2 (en) | Treatment of dyskinesia | |
| CN105451727A (zh) | 用于预防和/或治疗i型慢性创伤性脑病的方法 | |
| CN114887063A (zh) | Pacsin1在抑制瑞芬太尼诱发的痛觉过敏中的应用 | |
| CN111394356A (zh) | 一种内源性长链非编码rna mrak049966及其应用 |